Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome

about

Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion.Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

P2860

Q42025940-0C1103F8-2C29-4B23-9D6F-5B715F887357 Q51503406-D5A47A8E-DD2F-4775-BA1A-7E560D8597A8

P2860

Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome

Item

http://www.wikidata.org/entity/Q41807644

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bevacizumab for CRVO Associate ...... ctions on Final Visual Outcome

@en

type

Item

label

Bevacizumab for CRVO Associate ...... ctions on Final Visual Outcome

@en

prefLabel

Bevacizumab for CRVO Associate ...... ctions on Final Visual Outcome

@en

P1476

Bevacizumab for CRVO Associate ...... ctions on Final Visual Outcome

@en

P2093

Adi Sharabi-Nov

http://www.w3.org/2001/XMLSchema#string

Itzchak Beiran

http://www.w3.org/2001/XMLSchema#string

Joseph Pikkel

http://www.w3.org/2001/XMLSchema#string

Otzem Chassid

http://www.w3.org/2001/XMLSchema#string

Ward Srour

http://www.w3.org/2001/XMLSchema#string

Yumna Busool

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion

Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion

Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen

Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.

Venous occlusive disease: the latest in current management.

[Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland].

Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion.

Retinal vein occlusion and the prevalence of lipoprotein abnormalities.

Classification of central retinal vein occlusion.

Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion.

P304

974670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/974670

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260063387

http://www.w3.org/2001/XMLSchema#string

P698

24490054

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

3893752

http://www.w3.org/2001/XMLSchema#string

Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome

about

P2860

P2860

Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932